Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ivermectin - tablet - 3 mg - ivermectin 3 mg

Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 25 u/0.5 ml - hepatitis a virus (inactivated) 25 u/0.5 ml

Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - indinavir sulphate eqv indinavir - capsule - 200 mg - indinavir sulphate eqv indinavir 200 mg

Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - measles virus (more attenuated ender's strain) (live); mumps virus (jeryl lynn strain) (live); rubella virus (wistar ra 27/3 strain) (live) - injection, powder, for solution - min 1000 ccid50/0.5 ml - measles virus (more attenuated ender's strain) (live) min 1000 ccid50/0.5 ml; mumps virus (jeryl lynn strain) (live) min 12500 ccid50/0.5ml; rubella virus (wistar ra 27/3 strain) (live) min 1000 ccid50/0.5 ml

Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

Singapore - engleză - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - cilastatin sodium eqv cilastatin; imipenem - injection, powder, for solution - 500 mg/vial - cilastatin sodium eqv cilastatin 500 mg/vial; imipenem 500 mg/vial

Uniunea Europeană - engleză - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; povidone - adults (greater than or equal to 18 years) primary hypercholesterolaemia: - ezetimibe msd administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia. homozygous familial hypercholesterolaemia (hofh): - ezetimibe msd, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis). homozygous sitosterolaemia (phytosterolaemia): - ezetimibe msd is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,,prevention of cardiovascular disease ezetimibe msd is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a m

Australia - engleză - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; butylated hydroxyanisole; lactose monohydrate; hypromellose; microcrystalline cellulose; croscarmellose sodium; propyl gallate; citric acid monohydrate - adults (greater than or equal to 18 years),prevention of cardiovascular disease,ezetimibe/simvastatin msd is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties, clinical trials).,primary hypercholesterolaemia,ezetimibe/simvastatin msd is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe/simvastatin msd is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche) heterozygous familial hypercholesterolaemia (hefh),ezetimibe/simvastatin msd is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe/simvastatin msd is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 40 mg; ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; butylated hydroxyanisole; citric acid monohydrate; microcrystalline cellulose; croscarmellose sodium; propyl gallate; lactose monohydrate; hypromellose - adults (greater than or equal to 18 years),prevention of cardiovascular disease,ezetimibe/simvastatin msd is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties, clinical trials).,primary hypercholesterolaemia,ezetimibe/simvastatin msd is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe/simvastatin msd is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,children and adolescents 10-17 years,(pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche) heterozygous familial hypercholesterolaemia (hefh),ezetimibe/simvastatin msd is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,- patients not appropriately controlled with a statin or ezetimibe alone.,- patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe/simvastatin msd is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).